vs
Apellis Pharmaceuticals, Inc.（APLS）与Kimball Electronics, Inc.（KE）财务数据对比。点击上方公司名可切换其他公司
Kimball Electronics, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$341.3M vs $199.9M），Kimball Electronics, Inc.净利率更高（1.1% vs -29.5%，领先30.6%），Kimball Electronics, Inc.同比增速更快（-4.5% vs -5.9%），Kimball Electronics, Inc.自由现金流更多（$-11.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -10.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
金伯尔国际是一家美国企业，旗下拥有金伯尔、国民、Interwoven等多个家具品牌，业务涵盖酒店家具等多元产品线。它的前身是19至20世纪一度成为全球最大钢琴与管风琴制造商的W.W.金伯尔公司，如今转型聚焦商用家具领域发展。
APLS vs KE — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $341.3M |
| 净利润 | $-59.0M | $3.6M |
| 毛利率 | — | 8.2% |
| 营业利润率 | -25.6% | 3.2% |
| 净利率 | -29.5% | 1.1% |
| 营收同比 | -5.9% | -4.5% |
| 净利润同比 | -62.2% | 6.0% |
| 每股收益（稀释后） | $-0.40 | $0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $341.3M | ||
| Q3 25 | $458.6M | $365.6M | ||
| Q2 25 | $178.5M | $380.5M | ||
| Q1 25 | $166.8M | $374.6M | ||
| Q4 24 | $212.5M | $357.4M | ||
| Q3 24 | $196.8M | $374.3M | ||
| Q2 24 | $199.7M | $430.2M | ||
| Q1 24 | $172.3M | $425.0M |
| Q4 25 | $-59.0M | $3.6M | ||
| Q3 25 | $215.7M | $10.1M | ||
| Q2 25 | $-42.2M | $6.6M | ||
| Q1 25 | $-92.2M | $3.8M | ||
| Q4 24 | $-36.4M | $3.4M | ||
| Q3 24 | $-57.4M | $3.2M | ||
| Q2 24 | $-37.7M | $7.5M | ||
| Q1 24 | $-66.4M | $-6.1M |
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 8.0% | ||
| Q1 25 | — | 7.2% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | — | 6.3% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | — | 7.9% |
| Q4 25 | -25.6% | 3.2% | ||
| Q3 25 | 48.7% | 4.0% | ||
| Q2 25 | -18.6% | 4.3% | ||
| Q1 25 | -50.0% | 3.1% | ||
| Q4 24 | -12.3% | 2.3% | ||
| Q3 24 | -24.0% | 2.4% | ||
| Q2 24 | -14.7% | 4.6% | ||
| Q1 24 | -36.0% | -1.5% |
| Q4 25 | -29.5% | 1.1% | ||
| Q3 25 | 47.0% | 2.8% | ||
| Q2 25 | -23.6% | 1.7% | ||
| Q1 25 | -55.3% | 1.0% | ||
| Q4 24 | -17.1% | 1.0% | ||
| Q3 24 | -29.2% | 0.8% | ||
| Q2 24 | -18.9% | 1.8% | ||
| Q1 24 | -38.5% | -1.4% |
| Q4 25 | $-0.40 | $0.15 | ||
| Q3 25 | $1.67 | $0.40 | ||
| Q2 25 | $-0.33 | $0.27 | ||
| Q1 25 | $-0.74 | $0.15 | ||
| Q4 24 | $-0.30 | $0.14 | ||
| Q3 24 | $-0.46 | $0.12 | ||
| Q2 24 | $-0.30 | $0.29 | ||
| Q1 24 | $-0.54 | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $77.9M |
| 总债务越低越好 | — | $153.8M |
| 股东权益账面价值 | $370.1M | $579.2M |
| 总资产 | $1.1B | $1.1B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $77.9M | ||
| Q3 25 | $479.2M | $75.7M | ||
| Q2 25 | $370.0M | $88.8M | ||
| Q1 25 | $358.4M | $51.4M | ||
| Q4 24 | $411.3M | $53.9M | ||
| Q3 24 | $396.9M | $76.6M | ||
| Q2 24 | $360.1M | $78.0M | ||
| Q1 24 | $325.9M | $65.2M |
| Q4 25 | — | $153.8M | ||
| Q3 25 | — | $137.5M | ||
| Q2 25 | — | $147.1M | ||
| Q1 25 | — | $178.3M | ||
| Q4 24 | — | $204.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $294.8M | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $579.2M | ||
| Q3 25 | $401.2M | $577.1M | ||
| Q2 25 | $156.3M | $569.9M | ||
| Q1 25 | $164.2M | $548.1M | ||
| Q4 24 | $228.5M | $537.5M | ||
| Q3 24 | $237.1M | $547.8M | ||
| Q2 24 | $264.3M | $540.5M | ||
| Q1 24 | $266.7M | $539.1M |
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $821.4M | $1.1B | ||
| Q1 25 | $807.3M | $1.1B | ||
| Q4 24 | $885.1M | $1.1B | ||
| Q3 24 | $901.9M | $1.1B | ||
| Q2 24 | $904.5M | $1.2B | ||
| Q1 24 | $831.9M | $1.3B |
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.33× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $6.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-11.2M |
| 自由现金流率自由现金流/营收 | -7.1% | -3.3% |
| 资本支出强度资本支出/营收 | 0.1% | 5.3% |
| 现金转化率经营现金流/净利润 | — | 1.89× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $81.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $6.9M | ||
| Q3 25 | $108.5M | $8.1M | ||
| Q2 25 | $4.4M | $78.1M | ||
| Q1 25 | $-53.4M | $30.9M | ||
| Q4 24 | $19.4M | $29.5M | ||
| Q3 24 | $34.1M | $45.5M | ||
| Q2 24 | $-8.3M | $48.5M | ||
| Q1 24 | $-133.0M | $42.6M |
| Q4 25 | $-14.3M | $-11.2M | ||
| Q3 25 | $108.3M | $-2.5M | ||
| Q2 25 | $4.4M | $68.4M | ||
| Q1 25 | $-53.4M | $27.0M | ||
| Q4 24 | $19.3M | $23.1M | ||
| Q3 24 | — | $32.1M | ||
| Q2 24 | $-8.4M | $39.5M | ||
| Q1 24 | $-133.3M | $30.0M |
| Q4 25 | -7.1% | -3.3% | ||
| Q3 25 | 23.6% | -0.7% | ||
| Q2 25 | 2.5% | 18.0% | ||
| Q1 25 | -32.0% | 7.2% | ||
| Q4 24 | 9.1% | 6.5% | ||
| Q3 24 | — | 8.6% | ||
| Q2 24 | -4.2% | 9.2% | ||
| Q1 24 | -77.3% | 7.1% |
| Q4 25 | 0.1% | 5.3% | ||
| Q3 25 | 0.0% | 2.9% | ||
| Q2 25 | 0.0% | 2.5% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.0% | 3.6% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 0.2% | 3.0% |
| Q4 25 | — | 1.89× | ||
| Q3 25 | 0.50× | 0.80× | ||
| Q2 25 | — | 11.86× | ||
| Q1 25 | — | 8.11× | ||
| Q4 24 | — | 8.58× | ||
| Q3 24 | — | 14.42× | ||
| Q2 24 | — | 6.43× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
KE
| Automotive | $162.3M | 48% |
| Medical | $96.3M | 28% |
| Industrial | $82.7M | 24% |
